Related Experiment Video

Updated: May 21, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib

Maki Uyama1, Mari M Sato, Masamitsu Kawanami

  • 1Biochemistry and Molecular Biology, Graduate School of Dental Medicine, Hokkaido University, Sapporo, 060-8586, Japan.

Genes to Cells : Devoted to Molecular & Cellular Mechanisms
|June 19, 2012
PubMed

Insights

Proteasome inhibitors, like bortezomib, promote osteoblast differentiation by increasing osteocalcin expression and Runx2 activity in C2C12 cells. This suggests the ubiquitin-proteasome pathway regulates bone formation.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • The ubiquitin-proteasome pathway degrades intracellular proteins and is increasingly recognized for its role in bone metabolism.
  • Bortezomib, a proteasome inhibitor used in cancer therapy, has shown potential to increase bone formation.

Purpose of the Study:

  • To investigate the effect of proteasome inhibitors on osteoblastic differentiation in C2C12 cells.
  • To elucidate the molecular mechanisms by which proteasome inhibitors influence osteoblast differentiation, focusing on Runx2.

Main Methods:

  • Treatment of C2C12 cells with various proteasome inhibitors.
  • Analysis of osteoblastic differentiation markers (osteocalcin, alkaline phosphatase) and myogenic differentiation.
  • Reporter gene assays to assess promoter activity and signaling pathways (BMP/Smad).
  • Western blotting to evaluate protein levels and Runx2 binding activity.

Main Results:

  • Proteasome inhibitors, particularly bortezomib, significantly induced osteoblastic differentiation markers (osteocalcin, alkaline phosphatase) in C2C12 cells.
  • Myogenic differentiation was inhibited by proteasome inhibitors.
  • Bortezomib increased osteocalcin promoter activity, dependent on the OSE2 site, and enhanced Runx2 binding activity and protein levels.

Conclusions:

  • Proteasome inhibitors, including bortezomib, promote osteoblastic differentiation through modulation of Runx2 activity.
  • The ubiquitin-proteasome pathway plays a critical role in regulating osteoblast differentiation by controlling the degradation of key transcription factors.

More Related Videos

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...